Our Technology.
NanoDrug Delivery's core technology is an advanced nanoparticle system designed for the efficient transport of high drug load and controlled release of pharmaceutical drugs within the body. Our pioneering (Dual)-Hybrid-Nanoparticle technology features a unique structure with no current market equivalent. This breakthrough enables us to overcome major therapeutic challenges by increasing drug bioavailability, reducing toxicity, delivering activated drugs and unstable compounds and solving poor solubility issues.
01
Problems to be solved.
A: Chemistry Barriers
The pharmaceutical industry faces critical delivery challenges that prevent breakthrough treatments from reaching patients. Poor water solubility limits therapeutic potential by reducing bioavailability, while drug instability, premature metabolism, and complex activation requirements create additional barriers.
Most significantly, toxicity issues account for approximately 30% of all drug development failures, a devastating obstacle that keeps potentially life-saving therapies from those who need them most.
B: Reaching the Target
Equally critical is the challenge of precision delivery. Most drugs lack the ability to selectively target diseased tissues, resulting in minimal therapeutic concentration at the site of action while exposing healthy cells to unnecessary harm. This non-specific distribution not only causes severe side effects but also triggers cellular resistance mechanisms that reduce drug uptake and activation, ultimately compromising treatment outcomes.
C: Limitations of Current Nanoparticle-based Drug Delivery Systems
While nanoparticle drug delivery has gained industry recognition, existing technologies face critical limitations. Current platforms suffer from extremely low drug loading capacities (≤10%, often ≤1%), narrow chemical compatibility favoring only certain drugs, and complex manufacturing that hinders scalability.
We are developeding our (Dual)-Hybrid-Nanoparticle platform to systematically address each of these challenges and unlock new possibilities in targeted drug delivery.
02
Our Solution
Our patented nanoparticle delivery system features two chemically distinct platforms with revolutionary architectures that fundamentally differ from conventional approaches. Unlike existing systems where drugs merely bind to particle surfaces or dissolve in liquid compartments, leading to premature release and low drug loads, our technology integrates drugs as integral structural components.
​The simple structure of (Dual)-Hybrid-NP relies on electrostatic attraction between negatively charged drug molecules and a positively charged inorganic metal cation. Their solubility is pH-dependent. Besides drugs, they can encapsulate fluorescent dyes, contrast agents like Gd3+ or radioactively labeled metals like Zr98 for tracking via optical imaging, MRI, or PET. Surface functionalization with carbohydrates, antibodies, or peptides enables targeting specific cell types, improving delivery and therapeutic efficacy.
03
Hybrid and
Dual-Hybrid-Nanoparticle
Hybrid-NP are engineered specifically to transport, and release water-soluble anionicdrugs. They utilize a unique patented structure based on electrostatic attraction between negatively charged drug molecules and positively charged inorganic metal cations (ZrO]2+, La3+, Gd3+, Bi3+..), resulting in a stable amorphous nanoparticle structure, where the two components are evenly distributed. This elegant design achieves extremely high drug loads for this class of drugs that no other system has reached to date.
Dual-Hybrid-NP represent an even more sophisticated architecture: a pure drug core of a non-water-soluble drugs, surrounded by either an inactive protective shell or a second therapeutic drug. Alongside drugs and cationic metal species, they contain a surfactant such as biocompatible tocopheryl phosphate, a Vitamin E derivative. This breakthrough design enables unprecedented drug combinations and loading capacities impossible with traditional systems.
Both platforms offer exceptional versatility, accommodating fluorescent dyes, contrast drugs, and radioactive tracers for comprehensive tracking via optical imaging, MRI, or PET. This patented structural innovation represents a paradigm shift from conventional nanoparticle design to truly integrated drug particle systems.
04
How it works in Cancer
Nanoparticles can interact with diseased cells through various mechanisms, each offering unique advantages for therapeutic targeting. Due to cancer's significant clinical relevance and the well-characterized tumor microenvironment, cancer therapy serves as an exemplary model to illustrate these targeting principles.
In cancer, the Enhanced-Permeability-and-Retention (EPR) effect enables efficient nanoparticle transport to tumor sites. Tumor tissues often have leaky blood vessels with larger fenestrations, allowing nanoparticles to pass through and accumulate in the tumor microenvironment more effectively than in healthy tissues.
Functionalization of (Dual)-Hybrid-NP surfaces with targeting ligands, peptides or antibodies enhances delivery specificity by binding to receptors overexpressed on tumor cells or fibroblasts within the tumor microenvironment. Combining drugs with different mechanisms of action in our Dual-Hybrid-NP is particularly relevant in cancer therapy, overcoming tumor resistance and increasing the likelihood of killing more cancer cells. For other diseases, different targeting strategies apply. In bacterial infections such as tuberculosis, Hybrid-NP are designed to interact with immune cells like macrophages, which internalize the nanoparticles and release the therapeutic payload near the bacteria, improving efficacy while reducing systemic side effects.
The (Dual)-Hybrid-NP are primarily taken up by cells through mechanisms such as macropinocytosis, where cells engulf extracellular fluid and its contents, including nanoparticles, into large vesicles. Therefore, nanoparticle uptake is independent of specific transporters, usually responsible for drug uptake, which is also a mechanism of the (Dual)-Hybrid-NP to circumvent chemoresistance.
Next, (Dual)-Hybrid-NP progress along the endosomal pathway, and ultimately reach the lysosomes where the drug is released gradually over an extended period in the presence of low pH, ensuring a sustained therapeutic effect. This process is driven by the protonation of the drug molecules, which reduces their negative charge and thus the electrostatic attraction between the positively charged cations and the negatively charged drug molecules, leading to an increased solubility. Once the drug is released within the cell, it can exert its therapeutic effects.
05
Our Advantages
Our (Dual)-Hybrid-NP are produced via a simple, water-based synthesis that is cost-effective and considered highly scalable by industry experts. Many drugs require activation in the body to be effective. The (Dual)-Hybrid-NP architecture safely encloses such unstable molecules, protecting them from degradation and delivering them directly to the target site. Releasing the active form precisely at the site of action enhances efficacy and can help overcome resistance mechanisms, for example in cancer.
(Dual)-Hybrid-NP boast an extremely high drug load (up to 90%) compared to other nanodrug-delivery systems (≤10%) and contain far fewer pharmaceutically non-active components, which can be harmful, less biodegradable, or cause allergies. Their unique structure enables encapsulation of a broad range of drugs, including combinations with different modes of action within one particle. They can also carry drugs previously difficult to deliver due to properties like high water solubility or low stability in physiological media, thus expanding therapeutic options. Dual-Hybrid-NP are suitable and optimized for water-insoluble drugs enhancing their bioavailability and /or a combination of water-insoluble drugs with negatively charged water-soluble drugs, further increasing their variability.
